As the most common stem cell type being used within regenerative medicine, there is huge potential for growth within the mesenchymal stem cell (MSC) market. Today, MSCs are the most common stem cell type being used within clinical trials, as well as the most studied stem cell type within the scientific literature. [Read more…]
Utilization of Umbilical Cord Blood in HSCT versus Regenerative Medicine
(Percentage Breakdown)
Since its first successful use more than three decades ago, umbilical cord blood has become an increasingly important source of stem cells for transplants for bone marrow failures, leukemia, lymphoma, sickle cell anemia, and other life-threatening diseases. Over 40,000 cord blood transplants have been performed worldwide for a wide variety of malignant and non-malignant disorders. The first successful cord blood stem cell transplant was performed in 1988 as a treatment for a 5-year-old boy with Fanconi Anemia; his newborn sister’s umbilical cord blood saved his life. Today, more than 80 diseases have FDA-approved cord blood stem cell transplant treatments. [Read more…]
Cartherics Wins ‘Most Promising iPSC Therapy Pipeline in APAC’ at Asia Pacific Cell & Gene Therapy Excellence Awards
Melbourne, Australia, 11 September 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis, is proud to announce that it has been named ‘Most Promising iPSC Therapy Pipeline in APAC’ in the Asia Pacific Cell & Gene Therapy Excellence Awards 2025 (APCGTEA 2025). [Read more…]
What is Regenerative Medicine?
What is regenerative medicine? Put simply, regenerative medicine is the process of replacing or repairing human genes, cells, tissues or organs in order to restore healthy function. It is the processing of working with the human body to assist it to heal itself. In that sense, it is about working “with” biology, instead of “against” or “separate from” it. [Read more…]
European Commission Grants First Approval for Expanded Cord Blood Stem Cell Therapy (Zemcelpro®)
September 10, 2025 — In a landmark move for regenerative medicine, the European Commission has conditionally authorized Zemcelpro®, the first treatment in Europe to use expanded umbilical cord blood stem cells. Developed by Canadian biotech company ExCellThera, this therapy is only the second of its kind approved worldwide and represents a major advance in transplant options for patients with blood cancers such as leukemias and myelodysplastic syndromes. [Read more…]
- « Previous Page
- 1
- …
- 40
- 41
- 42
- 43
- 44
- …
- 334
- Next Page »